OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO

Rosario Mazzola, Barbara Alicja Jereczek-Fossa, Paolo Antognoni, Nadia Di Muzio, Luca Nicosia, Andrea Lancia, Ivan Fazio, Silvia Chiesa, Mattia F. Osti, Stefano Pergolizzi, Davide Franceschini, Piercarlo Gentile, Luca Triggiani, Filippo Alongi

Research output: Contribution to journalArticlepeer-review


In the last years, several evidences demonstrated the role of stereotactic body radiotherapy (SBRT) in the oligometastatic disease and the possibility to increase survival in selected patients. In 2020 the study group “biology and treatment of the oligometastatic disease” of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the attitude of physicians in treating the oligometastatic disease and the definition of it. An electronic questionnaire was administered online to the society members. 105 questionnaires were returned. 78% responders considered as oligometastatic a disease with ≤ 5 metastases. The majority of the responders (77%) treated > 50 patients in the last year, and 89% responders agreed in considering every oligometastatic tumor susceptible to local treatments. Regarding the clinical management of the oligometastatic disease, the majority of the responders (66%) suggested an interdisciplinary discussion. When choosing a treatment option for fit patients with a single oligometastatic focus, 52% of the responders agreed in proposing only SBRT. In the case of unfit patients with a single oligometastatic lesion the agreement was in favor of the SBRT alone (89%). In the oligoprogressive setting, 41% responders opted to continue the current systemic treatment and to add SBRT, while in the case of oligoresidual disease, 70% responders was in favor of adding SBRT and continuing the current systemic treatment. In conclusions, the survey illustrated the current agreement and prescribing attitude for oligometastatic patients in Italy. The non-homogenous agreement in some clinical scenarios suggest the need of more robust evidence.

Original languageEnglish
Article number48
JournalMedical Oncology
Issue number5
Publication statusPublished - May 2021


  • Oligometastatic disease
  • SABR
  • SBRT
  • Stereotactic body radiotherapy
  • Survey

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO'. Together they form a unique fingerprint.

Cite this